6 research outputs found
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
Type 2 diabetes mellitus (T2 DM) is often seen in patients with obesity. Bariatric surgery, aimed to decrease body weight, can often help those patientsto improve glycemic status. After some of bariatric operations patients reach normoglycemia in few days, the fact that cant be explained onlyby reduction in weight. Recent trials revealed that the reorganization of gastrointestinal tract provides hypoglycemic effect of such operations. Thisarticle explains the role of proximal and distal gut in pathophysiology of T2 DM
Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease
Aim.
To evaluate the prevalence of undiagnosed type 2 diabetes mellitus (T2DM) among patients with cardiovascular disease.
Materials and methods.
T2DM screening programs among patients with cardiovascular disease were held from 2013 to 2014 in several Russian cities. In total, 1001 patients aged β₯40 years with hypertension and/or atherosclerotic disease and without prior diagnosis of T2DM were screened in outpatient cardiology clinics. T2DM diagnosis was based on fasting plasma glucose levels, glycated haemoglobin (HbA1c) and/or oral glucose tolerance test (OGTT) results. Blood pressure (BP), family history of T2DM, cardiovascular disease, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglyceride levels were analysed.
Results.
Fasting glucose was measured in 1000 (99.8%) patients, HbA1c was measured in in 623 (62.2%) and OGTT was performed in 286 (2.6%). Fasting glucose detected 8% of newly diagnosed T2DM; among patients who underwentHbA1c measurement, the prevalence of T2DM was 10.91%, and among patients who underwent OGTT, the prevalence was 13.99%. Depending on the chosen test, the prevalence of undiagnosed pre-diabetes (impaired fasting glycaemia and impaired glucose tolerance) was in the range of 14.4%β36.4%. The majority of patients with T2DM diagnosed by OGTT did not have target blood pressure and lipid levels; 67.5% had elevated systolic BP, 47.5% had elevated diastolic BP, 90.9% had high LDL (β₯1.8 mmol/l) and 52.9% had high triglyceride levels (β₯1.7 mmol/l).
Conclusion.
A high prevalence of undiagnosed T2DM (from 8% to 13.99%, depending on the diagnostic criteria) and pre-diabetic state in patients with cardiovascular disease may require screening for T2DM in this high-risk group
Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity
Objective. Glucose-dependent insulinotropic polypeptide (GIP) as well as glucagon-like peptide-1 (GLP-1) is intestinal incretin hormone that stimulates insulin secretion in response to feeding. Much evidence of GIP contribution to obesity development has been found recently.Aim. The aim of the study was to evaluate glucose-stimulated GIP and GLP-1 secretion in people with type 2 diabetes (T2D) risk factors and different body mass index (BMI).Materials and methods. Total GIP and GLP-1 secretion was estimated in 127 patients with T2D risk factors during OGTT (75 g glucose) on 0, 30 and 120 minutes.Results. Patients with BMIβ₯ 35 kg/m2 had significantly higher fasting and stimulated GIP levels than participants with less BMI. GIP secretion was also higher in patients was insulinresistance, estimated by HOMA-IR, comparing to non-insulinresistant patients. Difference in GLP-1 secretion in patients within several BMI groups was nonsignificant.Conclusion. Our results suggest GIP is related to obesity degree, that means it can play a role in lipid metabolism and obesity development
Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow
Aims.
To assess the development of medical care and pharmacological treatment at Endocrine Research Centre (ERC), Moscow, forthe period of 2010-2011 years.Materials and Methods.
We analyzed files of 100 patients with type 2 diabetes mellitus (T2DM), who underwent hospitalization to ERCafter January 1, 2010. Key parameters were assessed by means of a study chart, applied for every patient file. Mean values, medians,fractions and confidence intervals (CI) were calculated for studied parameters. Various methods of parametric and non-parametricstatistics were used for comparison of acquired values.
Results.
Files of 100 patients with T2DM, hospitalized to Endocrinology Research Centre, were analyzed to obtain clinical characteristicsand evaluate initial (prior to hospitalization) and optimized (after hospitalization) therapeutic schemes, as well as spendingpatterns. Mean patient age exceeded 63 years, mean duration period of T2DM was greater than 14.4 years. 86% of patients weredecompensated for glycemic metabolism. 8% were diagnosed with less than 3 diabetes complications, 66% were found to have from 3to 6 complications. Almost all studied cases (98%) featured elevated blood pressure, 63% - diabetic retinopathy on different stages,59% - IHD, 51% - cataract, 49% - CKD. Lower limb angiopathy was found in 30% of cases, diabetic foot syndrome - in 15%.2 patients lost their vision due to diabetic complications and 3 patients experienced lower limb amputation. Arterial hypertension wascompensated in 14 cases from total of 98.Correction of therapy decreased fraction of patients on oral hypoglycemic agents and intermediate acting insulin (NPH), while prescriptionfrequency of short acting insulin and rapid acting human insulin analogues (as well as long acting analogues) showed oppositetrend. Optimization of therapy also included prescription of hypolipidemic drugs for majority of patients, as well as various agents forcorrection of coagulation abnormalities, treatment for CVD and other complications of T2DM.Due to described measures cost of per day treatment for 100 patients increased 2.28 times: from 8 982 RUB to 20 440 RUB (averagecost per day increased from 89.8 RUB to 204.1 RUB).Following the correction, fraction of patients with fasting glycemia 9.0 mmol/l dropped from 37% to 9%, and that with postprandial glycemia >10.0 mmol/l - from 27% to 1%.Mean fasting glycemia level decreased from 8.6 mmol/l to 6.8 mmol/l.Conducted analysis shows that prime expenditures (more that 36% from total cost structure) were associated with hospital stay (includingintensive care unit).
Conclusion.
Considering expanding nature of DM epidemic, there is an urgent need for effective healthcare management and preventionof severe cardiovascular complications. Priority should be established on balancing efficiency of hypoglycemic agents with theirsafety for short- and long-term prognosis
Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity
Objective. Glucose-dependent insulinotropic polypeptide (GIP) as well as glucagon-like peptide-1 (GLP-1) is intestinal incretin hormone that stimulates insulin secretion in response to feeding. Much evidence of GIP contribution to obesity development has been found recently.Aim. The aim of the study was to evaluate glucose-stimulated GIP and GLP-1 secretion in people with type 2 diabetes (T2D) risk factors and different body mass index (BMI).Materials and methods. Total GIP and GLP-1 secretion was estimated in 127 patients with T2D risk factors during OGTT (75 g glucose) on 0, 30 and 120 minutes.Results. Patients with BMIβ₯ 35 kg/m2 had significantly higher fasting and stimulated GIP levels than participants with less BMI. GIP secretion was also higher in patients was insulinresistance, estimated by HOMA-IR, comparing to non-insulinresistant patients. Difference in GLP-1 secretion in patients within several BMI groups was nonsignificant.Conclusion. Our results suggest GIP is related to obesity degree, that means it can play a role in lipid metabolism and obesity development
The 5th International Conference on Advanced Technologies Treatments for Diabetes (ATTD 2012),2012 February 8-11, Barcelona (Spain)
ΠΡΡΠ°Ρ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½Π°Ρ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½Π°Ρ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΡ ATTD (Advanced Technologies & Treatment for Diabetes) ΠΏΡΠΎΡΠ»Π° 8?11 ΡΠ΅Π²ΡΠ°Π»Ρ 2012 Π³ΠΎΠ΄Π° Π² ΠΡΠΏΠ°Π½ΠΈΠΈ (Π³. ΠΠ°ΡΡΠ΅Π»ΠΎΠ½Π°). ΠΠ°Π½Π½ΠΎΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠ΅ ΠΎΡΠ³Π°Π½ΠΈΠ·ΡΠ΅ΡΡΡ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ ΠΏΠΎΠ΄ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎΠΌ ΠΏΡΠΎΡ. Phillip Moshe (Institute for Endocrinology and Diabetes, Israel) ΠΈ Tadej Bottelino (University Children?s Hospital, Slovenia). Π 2012 Π³ΠΎΠ΄Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΡΠ΅Π·ΠΎΠ½Π°Π½Ρ Π² ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²Π΅ Π²ΡΠ·Π²Π°Π»ΠΈ ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΠΈ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΠΏΠΎΠΌΠΏΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π·Π°ΠΌΠΊΠ½ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΡΠ°?, ΡΠ΅Π»Π΅ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΈ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ. Π’ΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎ Π±ΡΠ» ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΡΠ΅ΡΠ΅Π΄Π½ΠΎΠΉ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΡΠΉ Π²ΡΠΏΡΡΠΊ ?ATTD Yearbook 2011? ? ΠΊΠΎΠ»Π»Π΅ΠΊΡΠΈΡ ΡΠ΅ΠΏΡΠΈΠ½ΡΠΎΠ² Π»ΡΡΡΠΈΡ
ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ
Π·Π° Π³ΠΎΠ΄ ΡΡΠ°ΡΠ΅ΠΉ ΠΏΠΎ Π½ΠΎΠ²ΡΠΌ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠΌ Π² Π΄ΠΈΠ°Π±Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ ΠΊΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΡΠΌΠΈ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ²